Scarica l'app Stockscreener
1.66
12.93%
0.19
Dopo l'orario di chiusura:
1.61
-0.05
-3.01%
Precedente Chiudi:
$1.47
Aprire:
$1.46
Volume 24 ore:
530.23K
Relative Volume:
0.45
Capitalizzazione di mercato:
$104.73M
Reddito:
$139.77M
Utile/perdita netta:
$-97.62M
Rapporto P/E:
-1.0506
EPS:
-1.58
Flusso di cassa netto:
$-61.71M
1 W Prestazione:
+3.11%
1M Prestazione:
+3.11%
6M Prestazione:
-32.52%
1 anno Prestazione:
-52.97%
Intervallo 1D:
$1.46
$1.67
Intervallo di 1 settimana:
$1.43
$1.67
Portata 52W:
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Confronta MGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.66 | 92.74M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-07 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-31 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-05-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Downgrade | Stifel | Buy → Hold |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2024-04-26 | Iniziato | B. Riley Securities | Buy |
| 2024-04-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-03-04 | Reiterato | BTIG Research | Buy |
| 2024-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
Short Term Charts Align With Long Term Uptrend in MacroGenics Inc.July 2025 Intraday Action & Weekly Market Pulse Updates - beatles.ru
MacroGenics Appoints Eric Risser As CEO - MarketScreener
MacroGenics names Eric Risser as new CEO, succeeding Scott Koenig By Investing.com - Investing.com Nigeria
MacroGenics Appoints Eric Risser as New CEO - TipRanks
MacroGenics appoints Eric Risser as new CEO, succeeding Scott Koenig By Investing.com - Investing.com Australia
MacroGenics Appoints Eric Risser as President and Chief Executive Officer - GlobeNewswire
MacroGenics Taps Deal-Making Expert Eric Risser as CEO After 24-Year Leadership Run Ends - Stock Titan
How liquid is MacroGenics Inc. stockBreakout Stocks for Quick Return - mustnews.co.kr
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. LawsuitMGNX - ACCESS Newswire
What makes MacroGenics Inc. stock price move sharplyFast-track wealth growth - Jammu Links News
What analysts say about MacroGenics Inc. stockUnmatched profit growth - Jammu Links News
How volatile is MacroGenics Inc. stock compared to the marketAccelerate your capital gains today - Jammu Links News
Does MacroGenics Inc. stock perform well during market downturnsInvest smarter with high-probability setups - Jammu Links News
What institutional investors are buying MacroGenics Inc. stockDynamic investment opportunities - Jammu Links News
What are the latest earnings results for MacroGenics Inc.Unbelievable profit margins - Jammu Links News
What are MacroGenics Inc. company’s key revenue driversHigh-yield investments - Jammu Links News
Is MacroGenics Inc. a growth stock or a value stockSuperior return velocity - Jammu Links News
How strong is MacroGenics Inc. company’s balance sheetEntry Signal Growth Plan For Every Investor - Jammu Links News
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics LawsuitMGNX - ACCESS Newswire
MacroGenics’ Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Why MacroGenics Inc. stock attracts strong analyst attentionTriple Digit Return Stock Predictions Released - metal.it
MacroGenics’ Phase 2 Study: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks
RSI and MACD Indicate Shift in MacroGenics Inc. SentimentProven Entry Plan With Low Risk Shared - metal.it
Is MacroGenics Inc. Starting a New UptrendBuy Low Sell High Stock Watch Strategy in Focus - metal.it
MacroGenics’ Promising Study on Advanced Solid Tumors: Key Insights for Investors - TipRanks
Will MacroGenics Inc. see short term momentumWeekly Trend Watch with Market Signals - Newser
What the charts say about MacroGenics Inc. todayGrowth Summary Based on Market Positioning - Newser
Analyzing MacroGenics Inc. with multi timeframe chartsFree Trend Following Strategy With Stop Loss - Newser
How does MacroGenics Inc. generate profit in a changing economyAchieve breakthrough gains with expert advice - Jammu Links News
What catalysts could drive MacroGenics Inc. stock higher in 2025Invest confidently with real-time market updates - Jammu Links News
What is MacroGenics Inc. company’s growth strategyRealize consistent double-digit growth - Jammu Links News
Why is MacroGenics Inc. stock attracting strong analyst attentionAchieve rapid wealth accumulation with smart picks - Jammu Links News
When is MacroGenics Inc. stock expected to show significant growthUnstoppable trading performance - Jammu Links News
How MacroGenics Inc. stock performs during market volatilityProven Return Strategy Execution - metal.it
Moving Average Trends for MacroGenics Inc. Stock: What They IndicateElite Stock Shortlist - Newser
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):